AU2013301609B2 - Methods and kits for screening patients with a cancer - Google Patents

Methods and kits for screening patients with a cancer Download PDF

Info

Publication number
AU2013301609B2
AU2013301609B2 AU2013301609A AU2013301609A AU2013301609B2 AU 2013301609 B2 AU2013301609 B2 AU 2013301609B2 AU 2013301609 A AU2013301609 A AU 2013301609A AU 2013301609 A AU2013301609 A AU 2013301609A AU 2013301609 B2 AU2013301609 B2 AU 2013301609B2
Authority
AU
Australia
Prior art keywords
cancer
patients
ren
pdcd1
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013301609A
Other languages
English (en)
Other versions
AU2013301609A1 (en
Inventor
Gabriela BINDEA
Jerome Galon
Bernhard Mlecnik
Franck Pages
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Cite filed Critical Assistance Publique Hopitaux de Paris APHP
Publication of AU2013301609A1 publication Critical patent/AU2013301609A1/en
Application granted granted Critical
Publication of AU2013301609B2 publication Critical patent/AU2013301609B2/en
Assigned to ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Universite De Paris reassignment ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Request for Assignment Assignors: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES
Assigned to ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITÉ PARIS CITÉ reassignment ASSISTANCE PUBLIQUE HOPITAUX DE PARIS Request to Amend Deed and Register Assignors: Universite De Paris, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2013301609A 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer Active AU2013301609B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305975.0 2012-08-06
EP12305975 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Publications (2)

Publication Number Publication Date
AU2013301609A1 AU2013301609A1 (en) 2015-02-26
AU2013301609B2 true AU2013301609B2 (en) 2019-03-14

Family

ID=46762994

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013301609A Active AU2013301609B2 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Country Status (13)

Country Link
US (2) US20150218650A1 (enExample)
EP (2) EP3470531A1 (enExample)
JP (2) JP6559566B2 (enExample)
AU (1) AU2013301609B2 (enExample)
CA (1) CA2881389C (enExample)
DK (1) DK2880180T3 (enExample)
ES (1) ES2702722T3 (enExample)
LT (1) LT2880180T (enExample)
PL (1) PL2880180T3 (enExample)
PT (1) PT2880180T (enExample)
SG (1) SG11201500922RA (enExample)
TR (1) TR201819211T4 (enExample)
WO (1) WO2014023706A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3232199B1 (en) * 2014-08-19 2022-05-04 National University Corporation Okayama University Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
JP6565093B1 (ja) 2018-03-22 2019-08-28 住友電工ハードメタル株式会社 表面被覆切削工具およびその製造方法
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
IL291748A (en) 2019-11-07 2022-06-01 Oncxerna Therapeutics Inc Classification of growth microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
CA3245129A1 (en) 2022-03-17 2023-09-21 Univ Paris Cite METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024043A2 (en) * 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
AU2006239315B2 (en) 2005-04-28 2012-03-01 Ventana Medical Systems, Inc. Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
EP3095467B1 (en) 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
EP2619576B1 (en) * 2010-09-24 2020-06-10 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005024043A2 (en) * 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Also Published As

Publication number Publication date
WO2014023706A1 (en) 2014-02-13
CA2881389A1 (en) 2014-02-13
SG11201500922RA (en) 2015-04-29
DK2880180T3 (en) 2019-01-14
JP6559566B2 (ja) 2019-08-14
ES2702722T3 (es) 2019-03-05
AU2013301609A1 (en) 2015-02-26
EP3470531A1 (en) 2019-04-17
JP6995091B2 (ja) 2022-01-14
PT2880180T (pt) 2018-12-27
US20150218650A1 (en) 2015-08-06
CA2881389C (en) 2022-01-04
PL2880180T3 (pl) 2019-04-30
JP2015530877A (ja) 2015-10-29
US20200299784A1 (en) 2020-09-24
TR201819211T4 (tr) 2019-01-21
EP2880180A1 (en) 2015-06-10
JP2019176880A (ja) 2019-10-17
LT2880180T (lt) 2019-01-25
EP2880180B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
US20200299784A1 (en) Methods and kits for screening patients with cancer
US12291752B2 (en) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
AU2017261685B2 (en) Methods for classifying patients with a solid cancer
US20250320564A1 (en) Methods and kits for treatment of cancer patients who are good responders to antitumoral treatment
JP2022174309A (ja) がんの重症度を評価するためのｔｉｍ－３
WO2017055322A1 (en) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055320A1 (en) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
HK40007449B (en) Methods for classifying patients with a solid cancer
HK40007449A (en) Methods for classifying patients with a solid cancer
BR112018072993B1 (pt) Método in vitro para o prognóstico do tempo de sobrevivência de um paciente que sofre de um câncer sólido e método in vitro para avaliar a capacidade de resposta de um paciente que sofre de um câncer sólido a um tratamento antitumoral

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Free format text: FORMER OWNER(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER OWNER(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: UNIVERSITE DE PARIS

Free format text: FORMER OWNER(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; UNIVERSITE PARIS DESCARTES; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

HB Alteration of name in register

Owner name: UNIVERSITE PARIS CITE

Free format text: FORMER NAME(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE PARIS

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER NAME(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE PARIS

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Free format text: FORMER NAME(S): ASSISTANCE PUBLIQUE HOPITAUX DE PARIS; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE PARIS